We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
- Authors
O'Brien, M E R; Wigler, N; Inbar, M; Rosso, R; Grischke, E; Santoro, A; Catane, R; Kieback, D G; Tomczak, P; Ackland, S P; Orlandi, F; Mellars, L; Alland, L; Tendler, C; CAELYX Breast Cancer Study Group
- Abstract
This study was designed to demonstrate that efficacy [progression-free survival (PFS)] of CAELYX [pegylated liposomal doxorubicin HCl (PLD)] is non-inferior to doxorubicin with significantly less cardiotoxicity in first-line treatment of women with metastatic breast cancer (MBC).
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Vol 15, Issue 3, p440
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdh097